Emergency Medicine Reports - August 20, 2006

Target Audience:

This continuing medical education activity is intended for emergency physicians.


AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CME Question Reviewer
Roger Farel, MD
Newport Beach, CA

Robert G. Hendrickson, MD
Assistant Professor
Department of Emergency Medicine
Oregon Health and Science University
Associate Medical Director
Oregon Poison Center

Laura Spivak, MD
Medical Toxicology Fellow
Oregon Poison Center
Emergency Medicine
Oregon Health and Science University

Peer Reviewers
John G. Benitez, MD, MPH, FACMT
Ruth A. Lawrence Poison and Drug Information Center
Associate Professor of Emergency Medicine
Environmental Medicine and Pediatrics
University of Rochester, NY

Thomas G. Martin, MD, MPH, FACMT, FAACT, FACEP
Associate Professor of Medicine
Division of Emergency Medicine
UW-TOX (UW Med Tox Consult Service)
Associate Medical Director
Washington Poison Center
Attending Physician
UWMC Emergency Department
Seattle, WA

Sandra M. Schneider, MD
Professor and Chair
Department of Emergency Medicine
University of Rochester School of Medicine
Rochester, New York

J. Stephan Stapczynski, MD
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Gideon Bosker, MD
Special Clinical Projects
Medical Education Resources
Assistant Clinical Professor
Section of Emergency Services
Yale University School of Medicine
New Haven, Connecticut


  • Methamphetamine


  • quickly recognize or increase index of suspicion for specific conditions
  • understand the epidemiology, etiology, pathophysiology, and clinical features of the entity discussed
  • apply state-of-the-art diagnostic and therapeutic techniques (including the implications of pharmaceutical therapy discussed) to patients with the particular medical problems discussed
  • understand the differential diagnosis of the entity discussed
  • understand both likely and rare complications that may occur

Financial Disclosure:

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Roger Farel, MD (CME question reviewer) owns stock in Johnson & Johnson. Robert G. Hendrickson, MD, Laura Spivak, MD (authors), John G. Benitez, MD, MPH, FACMT, Thomas G. Martin, MD, MPH, FACMT, FAACT, FACEP (peer reviewers), and Sandra M. Schneider, MD (editor) report no relationships with companies related to the field of study covered by this CME activity. J. Stephan Stapczynski, MD (editor) reports that he served as a consultant to Pfizer on the drugs linezolid and dalbavancin. Gideon Bosker, MD (editor in chief) has been compensated for speaking engagements and/or editorial services related to production of peer-reviewed Clinical Consensus Reports under the auspices of unrestricted educational grants for Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Roche Pharmaceuticals, Bayer, Novartis, Forest Pharmaceuticals, and Schering Plough Corporation. Dr. Bosker also acknowledges that he has received royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and/or other electronic or print materials to the following pharmaceutical companies: Pfizer, Sanofi-Aventis, Bayer, Roche, Forest Laboratories, and Novartis. He is a minor stockholder in Pfizer. Any other stock ownership which he may have in other pharmaceutical companies is managed in blinded fashion by an independent consultant without Dr. Bosker's input or consultation.

Copyright 2006 AHC Media. All rights reserved.